Skip to main content

Advertisement

SpringerLink
Log in

Why I Use Subcutaneous Immunoglobulin (SCIG)

  • Published:
Journal of Clinical Immunology Aims and scope Submit manuscript

Abstract

Immunoglobulin (IgG) replacement is a life-saving treatment for individuals with primary immunodeficiency disease (PIDD). Today, there are many options for IgG replacement, and the choice is an individual one based on many factors. My preference for most patients is the subcutaneous (SCIG) route. It offers many advantages not offered by the intravenous (IVIG) route. These include: 1) independence from hospital-based infusion settings; 2) an alternative for patients with poor venous access; 3) better tolerability in those patients who are not able to tolerate IVIG; 4) flexibility of dosing; 5) ease of administration; 6) a very low side-effect profile; 7) a comparatively more even, almost physiological, IgG level; 8) less cost to administer than IVIG; and 9) improved quality of life in patients treated with SCIG compared with those treated with IVIG. For most patients with PIDD who require IgG replacement, SCIG offers advantages not available with IVIG.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Berger M. Subcutaneous immunoglobulin replacement in primary immunodeficiencies. Clin Immunol. 2004;112:1–7.

    Article  PubMed  CAS  Google Scholar 

  2. Gardulf A, Hammarstrom L, Smith CIE. Home treatment of hypogammaglobulinaemia with subcutaneous gammaglobulin by rapid infusion. Lancet. 1991;338:162–6.

    Article  PubMed  CAS  Google Scholar 

  3. Hizentra, Immune Globulin Subcutaneous (Human), 20 % Liquid. CSL Behring AG, Bern, Switzerland; March 1, 2010. Available at: http://www.hizentra.com/docs/hizentraPI.pdf. Accessed Nov. 16, 2012.

  4. GAMMAGARD LIQUID [Immune Globulin Infusion (Human)] 10 % Solution, for intravenous and subcutaneous administration. Westlake Village, CA: Baxter Healthcare Corporation; 2012. Available at: http://www.baxter.com/products/biopharmaceuticals/downloads/gamliquid_PI.pdf. Accessed Nov. 16, 2012.

  5. Vivaglobin (Immune Globulin Subcutaneous [Human]). CSL Behring GmbH; 2006. Available at: http://www.cslbehring.com/docs/31/247/Vivaglobin%20April%2010%20PI,0.pdf. Accessed Nov. 16, 2012.

  6. Gardulf A, Nicolay U, Math D, Asensio O, Bernatowska E, Böck A, et al. Children and adults with primary antibody deficiencies gain quality of life by subcutaneous IgG self-infusions at home. J Allergy Clin Immunol. 2004;114:936–42.

    Article  PubMed  CAS  Google Scholar 

  7. Berger M, Rojavin M, Kiessling P, Zenker O. Pharmacokinetics of subcutaneous immunoglobulin and their use in dosing of replacement therapy in patients with primary immunodeficiencies. Clin Immunol. 2011;139:133–41.

    Article  PubMed  CAS  Google Scholar 

  8. Skoda-Smith S, Torgerson TR, Ochs HD. Subcutaneous immunoglobulin replacement therapy in the treatment of patients with primary immunodeficiency disease. Ther Clin Risk Manag. 2010;6:1–10.

    PubMed  CAS  Google Scholar 

  9. Chapel HM, Spickett GP, Ericson D, Engl W, Eibl MM, Bjorkander J. The comparison of the efficacy and safety of intravenous versus subcutaneous immunoglobulin replacement therapy. J Clin Immunol. 2000;20:94–100.

    Article  PubMed  CAS  Google Scholar 

  10. Asia Pacific Immunoglobulins in Immunology Expert Group. Consensus Recommendations for the use of Immunoglobulin Replacement Therapy in Immune Deficiency. 2009. Available at: http://www.info4pi.org/Documents/Publications/APIIEG%20Consensus%20Recommendations%20Edition%202%20July%202009_20120201_170745.pdf. Accessed Nov. 16, 2012.

  11. Fasth A, Nyström J. Quality of life and health-care resource utilization among children with primary immunodeficiency receiving home treatment with subcutaneous human immunoglobulin. J Clin Immunol. 2008;28:370–8.

    Article  PubMed  CAS  Google Scholar 

  12. Moore ML, Quinn JM. Subcutaneous immunoglobulin replacement therapy for primary antibody deficiency: advancements into the 21st century. Ann Allergy Asthma Immunol. 2008;101:114–21.

    Article  PubMed  CAS  Google Scholar 

Download references

Conflict of interest

The author serves on advisory boards and as a consultant to CSL Behring, Baxter, DNAX, and Virapharma. He is a principal investigator for CSL Behring, Baxter, and Virapharma.

Author information

Authors and Affiliations

  1. Midwest Immunology Clinic, 157300 37th Avenue, Suite 100, Plymouth, MN, 55446, USA

    Ralph S. Shapiro

Authors
  1. Ralph S. Shapiro
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ralph S. Shapiro.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Shapiro, R.S. Why I Use Subcutaneous Immunoglobulin (SCIG). J Clin Immunol 33 (Suppl 2), 95–98 (2013). https://doi.org/10.1007/s10875-012-9853-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10875-012-9853-2

Keywords

Search

Navigation